Enzymatica AB (publ) (STO:ENZY)

Market Cap	475.76M +28.9%
Revenue (ttm)	53.90M +18.3%
Net Income	-51.89M
EPS	-0.21
Shares Out	242.74M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,718
Average Volume	91,163
Open	1.960
Previous Close	1.960
Day's Range	1.925 - 1.990
52-Week Range	1.600 - 5.450
Beta	0.35
RSI	54.59
Earnings Date	Feb 18, 2026

About Enzymatica AB

Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases. The company’s product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care. The company was incorporated in 2007 and is headquartered in Lund, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 20
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ENZY

Financial Performance

In 2025, Enzymatica AB's revenue was 53.90 million, an increase of 18.27% compared to the previous year's 45.58 million. Losses were -51.89 million, -2.42% less than in 2024.